Denise Jaggers
Duke University(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Glioma Diagnosis and Treatment, RNA Interference and Gene Delivery, Cancer Research and Treatments, Cytomegalovirus and herpesvirus research
Most-Cited Works
- → Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients(2014)263 cited
- → Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo(2010)144 cited
- → Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial(2023)45 cited
- → A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial(2025)8 cited
- → CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL(2020)6 cited
- → Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.(2024)5 cited
- → 48th Annual Meeting of the International Society for Pediatric Neurosurgery(2022)3 cited
- → IMMU-06. TARGETING IDH1 MUTANT GRADE II RECURRENT GLIOMAS USING A PEPTIDE VACCINATION STRATEGY(2021)3 cited
- → EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL(2021)3 cited
- → CTIM-15. RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA(2022)1 cited